A. Trotti, A. Colevas, A. Setser, V. Rusch, D. Jaques et al., CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment, Seminars in Radiation Oncology, vol.13, issue.3, pp.176-181, 2003.
DOI : 10.1016/S1053-4296(03)00031-6

T. Atkinson, Y. Li, C. Coffey, L. Sit, M. Shaw et al., Reliability of adverse symptom event reporting by clinicians, Quality of Life Research, vol.24, issue.7, pp.1159-1164, 2012.
DOI : 10.1200/JCO.2005.02.8332
URL : http://europepmc.org/articles/pmc3633532?pdf=render

M. Palazzi, S. Tomatis, E. Orlandi, M. Guzzo, C. Sangalli et al., Effects of Treatment Intensification on Acute Local Toxicity During Radiotherapy for Head and Neck Cancer: Prospective Observational Study Validating CTCAE, Version 3.0, Scoring System, International Journal of Radiation Oncology*Biology*Physics, vol.70, issue.2, pp.330-337, 2008.
DOI : 10.1016/j.ijrobp.2007.06.022

G. Jiang, L. Wang, H. Liu, H. Solbrig, and C. Chute, Building a knowledge base of severe adverse drug events based on AERS reporting data using semantic web technologies, Stud Health Technol Inform, vol.192, pp.496-500, 2013.

H. Bergman, T. Walton, D. Bel, R. Seki, J. Rafii et al., Managing skin toxicities related to panitumumab, Journal of the American Academy of Dermatology, vol.71, issue.4, pp.754-759, 2014.
DOI : 10.1016/j.jaad.2014.06.011

, Support Care Cancer

M. Lacouture, M. Maitland, S. Segaert, A. Setser, R. Baran et al., A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group, Supportive Care in Cancer, vol.25, issue.13, pp.509-522, 2010.
DOI : 10.1007/s00520-009-0744-x

A. Chan and E. Tan, How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?, Supportive Care in Cancer, vol.115, issue.10, pp.1667-1674, 2011.
DOI : 10.1002/cncr.24120

V. Sibaud, J. Delord, and C. Robert, Dermatology and anticancer therapies: practical handbook. Editions Privat, 2015.

T. Lynch, . Jr, E. Kim, B. Eaby, J. Garey et al., Epidermal Growth Factor Receptor Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management, The Oncologist, vol.12, issue.5, pp.610-621, 2007.
DOI : 10.1634/theoncologist.12-5-610

A. Gonzalez-sanchis, A. Vicedo-gonzalez, L. Brualla-gonzalez, J. Gordo-partearroyo, R. Inigo-valdenebro et al., Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations, Clinical and Translational Oncology, vol.100, issue.3, pp.892-897, 2014.
DOI : 10.1016/j.radonc.2011.02.004

Y. Liu, G. Zhu, and X. Guan, Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma, Oral Oncology, vol.48, issue.6, pp.554-559, 2012.
DOI : 10.1016/j.oraloncology.2012.01.004

J. Deng, S. Ridner, M. Dietrich, N. Wells, and B. Murphy, Assessment of External Lymphedema in Patients With Head and Neck Cancer: A Comparison of Four Scales, Oncology Nursing Forum, vol.40, issue.5, pp.501-506, 2013.
DOI : 10.1188/13.ONF.501-506

A. Eisbruch, N. Rhodus, D. Rosenthal, B. Murphy, C. Rasch et al., How should we measure and report radiotherapy-induced xerostomia?, Seminars in Radiation Oncology, vol.13, issue.3, pp.226-234, 2003.
DOI : 10.1016/S1053-4296(03)00033-X

L. Peuvrel and B. Dreno, Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management, American Journal of Clinical Dermatology, vol.25, issue.2, pp.425-444, 2014.
DOI : 10.1097/CAD.0000000000000032

M. Lacouture, M. Anadkat, R. Bensadoun, J. Bryce, A. Chan et al., Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities, Supportive Care in Cancer, vol.18, issue.5, pp.1079-1095, 2011.
DOI : 10.1007/s00520-009-0744-x
URL : https://link.springer.com/content/pdf/10.1007%2Fs00520-011-1197-6.pdf

A. Russo and A. Taghian, Fat necrosis of the breast in the accelerated partial breast irradiation era: the need for a universal grading system, Breast Cancer Research and Treatment, vol.58, issue.4, pp.1-11, 2013.
DOI : 10.1016/j.ijrobp.2003.08.013

L. Fine and J. Bernstein, Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines, Current Allergy and Asthma Reports, vol.29, issue.6, p.30, 2015.
DOI : 10.1385/CRIAI:29:1:003

K. Williams and H. Sharma, Anaphylaxis and Urticaria, Immunology and Allergy Clinics of North America, vol.35, issue.1, pp.199-219, 2015.
DOI : 10.1016/j.iac.2014.09.010

J. Macdonald, B. Macdonald, L. Golitz, P. Lorusso, and A. Sekulic, Cutaneous adverse effects of targeted therapies, Journal of the American Academy of Dermatology, vol.72, issue.2, pp.203-218, 2015.
DOI : 10.1016/j.jaad.2014.07.032

S. Zenda, Y. Ota, H. Tachibana, H. Ogawa, S. Ishii et al., A prospective picture collection study for a grading atlas of radiation dermatitis for clinical trials in head-and-neck cancer patients, Journal of Radiation Research, vol.355, issue.3, pp.301-306, 2016.
DOI : 10.1093/jjco/hyv010

A. Lencioni, L. Hutchins, A. S. Chen, W. Ermisoglu, E. Feng et al., An adverse event capture and management system for cancer studies, BMC Bioinformatics, vol.348, issue.4, p.6, 2015.
DOI : 10.1056/NEJMsa020847
URL : https://bmcbioinformatics.biomedcentral.com/track/pdf/10.1186/1471-2105-16-S13-S6?site=bmcbioinformatics.biomedcentral.com

E. Basch, B. Reeve, S. Mitchell, S. Clauser, L. Minasian et al., Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), JNCI Journal of the National Cancer Institute, vol.103, issue.24, 2014.
DOI : 10.1093/jnci/djr493

A. Dueck, T. Mendoza, S. Mitchell, B. Reeve, K. Castro et al., Validity and Reliability of the US National Cancer Institute???s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), JAMA Oncology, vol.1, issue.8, pp.1051-1059, 2015.
DOI : 10.1001/jamaoncol.2015.2639

J. Hay, T. Atkinson, B. Reeve, S. Mitchell, T. Mendoza et al., Cognitive interviewing of the US National Cancer Institute???s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), Quality of Life Research, vol.12, issue.4, pp.257-269, 2014.
DOI : 10.1001/jama.2012.466

P. Kluetz, D. Chingos, E. Basch, and S. Mitchell, Patientreported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE), Am Soc Clin Oncol Educ Book, vol.35, pp.67-73, 2016.